herbert.ou

[herbert.ou @herbert_ou]

@AppleHelix To keep invite emails, create a rule: header X-Ms-Traffictypediagnostic contains MeetingMessage → action Copy to Mailbox (e.g., “Invites Archive”). This backs them up before Mail moves them to Trash. Mainly works for Exchange/Office 365, rules run only while Mail is open.

[herbert.ou @herbert_ou]

in Chinese:https://t.co/5ueft5dUNj

[herbert.ou @herbert_ou]

Today Sino Biopharm & Boehringer Ingelheim sign deal on Nov 4 for 6 preclinical assets (ADCs/T-cell engagers). $358M upfront, up to $7B milestones + royalties. BI gets global rights after Phase I. A key step in oncology innovation. @JacobPlieth

[Paolo Tarantino @PTarantinoMD]

3 practice refinements after #ESMO26:

1. Always offer screening brain MRI at metastatic diagnosis (HER2+/TN) and offer 1L ADCs in case of BM

2. Consider adding tucatinib to HP after local therapy for brain-only PD while on 1L HP maintenance

3. Limit sequential TOPO1 ADCs

[Paolo Tarantino @PTarantinoMD]

Switching ADC target does not work. Switching payload does.

Among 60 TOPO1-ADC-pretreated patients with MBC, using a microtubule (MMAE) ADC led to 30% ORR and DoR of 8.8 mo. #ESMO26 #ESMOAmbassadors

[herbert.ou @herbert_ou]

@JacobPlieth Both cooperation, 2 preclinical from Hansoh and some targets from RHHBY , it's a development biotech investing, same as innocent with Pfizer

[herbert.ou @herbert_ou]

$3692.HK Hansoh signs strategic ADC deal with Roche: $400M upfront + $110M anniversary; eligible for >$15B milestones + tiered royalties. Hansoh leads early dev to global Ph Ia; Roche develops ex-Greater China; Hansoh keeps Greater China rights. #ADC #biotech @jacobplieth

[herbert.ou @herbert_ou]

@JacobPlieth you are always correct https://t.co/26VPU4Ad6b

[herbert.ou @herbert_ou]

@JacobPlieth @raffcolo Thanks so much

[Minhua Chu @chuminhua432]

$NVS signs a $7.8B+ deal with 🇨🇳 Abogen Biosciences to advance mRNA-encoded therapeutics, including an in vivo CD19xCD3 T-cell engager for autoimmune diseases. https://t.co/HYCto8bCqR

💰 Deal terms:
• $575M upfront
• Up to ~$7.2B in potential milestone payments if all options are exercised
• Potential royalties on future product sales
• Exclusive worldwide license to lead asset ABO2203
• Options to exclusively license additional programs from Abogen’s RNA platform

ABO2203 is an mRNA-encoded CD19xCD3 T-cell engager.

Abogen says ABO2203 is the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases.

Founded around RNA innovation, Abogen has an AI- and automation-driven mRNA/LNP platform.
Its pipeline covers oncology, autoimmune diseases and vaccines, including ABO1108, a lyophilized mRNA shingles vaccine in Phase 3 trials in China.

[Ed Reznik @EdReznik]

Incredibly excited to report today on the determinants of toxicity to systemic therapy in cancer patients. Led by many including Alex Guo, Feiyang Huang, Saksham Mohan, River Walser, and the fearless @ZiadBakouny. Co-led by Wes Tansey and Jian Carrot-Zhang https://t.co/axflh9pMRS

[brian lipworth @doclip1]

Tozorakimab to Prevent COPD Exacerbations | New England Journal of Medicine https://t.co/PBjoZ0rRfv

Need to treat an average patient for 1.4 years to prevent an exacerbation in former smokers and 1.7 years in current and former smokers

[herbert.ou @herbert_ou]

Exciting news for COPD patients! 🫁 Mabwell 9MW1911 just delivered incredible Phase Ib/IIa results, showing the best clinical data for COPD so far. A huge step forward in reducing severe exacerbations! 🌟 #COPD

[L2P Research Labs @l2presearch]

ERS 2026 | Mabwell Presents Phase Ib/IIa Clinical Results of Anti-ST2 Monoclonal Antibody 9MW1911 in COPD Patients https://t.co/yKMBAA1Y2l

[MIT Chemistry @ChemistryMIT]

Professor of Chemistry and Broad Institute Core Member Xiao Wang has been selected as the recipient of the 2027 Eli Lilly Award in recognition of her fundamental research in Biological Chemistry.

https://t.co/JAl9u06dMR

[herbert.ou @herbert_ou]

@JacobPlieth Yes,BG-68501, BG-60366, BG-89894 & BGB-53038 discontinued

[herbert.ou @herbert_ou]

Chinese biotech firms are improving rapidly, and American firms fear losing market dominance. The real issue is not espionage but competition.

[herbert.ou @herbert_ou]

@GeneInvesting @PeterKolchinsky Is there any goddamn evidence that Chinese companies are "stealing" IP? This is absolutely disgusting!